ANGO vs BDX
ANGO: A medical technology company specializing in image-guided, minimally invasive devices for cardiovascular disease, vascular access, and oncology treatments. BDX: A global medical technology leader providing essential healthcare supplies, diagnostic systems, and biosciences research tools to improve patient outcomes.
Side-by-side fundamentals
| Metric | ANGO | BDX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $11.23 | $182.75 | |
| Market cap | $472M | $49.8B | |
| P/E as of 2026-10-08 | n/a | 55.14 | |
| Net margin | -11.5% | +7.7% | BDX higher |
| Gross margin FY2026, SEC XBRL | +54.6% | n/a | |
| Operating margin | -12.5% | +11.8% | BDX higher |
| ROE | -21.5% | +6.6% | BDX higher |
| ROA | -13.8% | +3.0% | BDX higher |
| Debt / equity as of 2026-09-03 | 0.03 | 0.69 | ANGO lower |
| Revenue growth (YoY) as of 2026-09-03 | +9.5% | -2.6% | ANGO higher |
| Revenue CAGR (3y) SEC XBRL | -1.9% | +5.0% | BDX higher |
| Dividend yield as of 2026-09-03 | n/a | +2.3% | |
| Dividend streak (yrs) SEC XBRL | 0 | 13 | BDX higher |
| Beta as of 2026-09-03 | 1.02 | 0.45 | |
| 1-year return as of 2026-10-08 close | +1.0% | +19.9% | BDX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.